(Q39155554)

9 September 2017

title

HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay (English)

1 reference

9 September 2017

Dominique Schols

11

0 references

author name string

Jean Labrecque

1

1 reference

9 September 2017

Markus Metz

2

1 reference

9 September 2017

Gloria Lau

3

1 reference

9 September 2017

Marilyn C Darkes

4

1 reference

9 September 2017

Rebecca S Y Wong

5

1 reference

9 September 2017

David Bogucki

6

1 reference

9 September 2017

Bryon Carpenter

7

1 reference

9 September 2017

Gang Chen

8

1 reference

9 September 2017

Tongshuang Li

9

1 reference

9 September 2017

Susan Nan

10

1 reference

9 September 2017

Gary J Bridger

12

1 reference

9 September 2017

Simon P Fricker

13

1 reference

9 September 2017

Renato T Skerlj

14

1 reference

9 September 2017

language of work or name

English

0 references

publication date

9 March 2011

1 reference

9 September 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

9 September 2017

volume

413

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

231-243

1 reference

Chemokine: receptor structure, interactions, and antagonism

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

A new classification for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

GlaxoSmithKline ends aplaviroc trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

An overview of the determinants of CCR5 and CXCR4 co-receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

G-protein coupled receptors as allosteric machines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

New concepts in drug discovery: collateral efficacy and permissive antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Treatment of HIV infection with the CCR5 antagonist maraviroc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

HIV and the chemokine system: 10 years later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Structural and molecular interactions of CCR5 inhibitors with CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

CCR5 pharmacology methodologies and associated applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

New HIV Drugs in Development, 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Heavier-than-air flying machines are impossible.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Chemokines, chemokine receptors and small-molecule antagonists: recent developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Maraviroc: a new CCR5 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Advances in Determination of a High-Resolution Three-Dimensional Structure of Rhodopsin, a Model of G-Protein-Coupled Receptors (GPCRs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.02.016

10.1016/J.VIROL.2011.02.016

7 January 2021

Identifiers

DOI

1 reference

9 September 2017

1 reference